Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | PNP | P00491 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | EDNRA | P25101 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HBB | P68871 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HPRT1 | P00492 | 12/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omaciclovir SCHEMBL417577 | 1.00 | TK1 (0.62) | TK1BLMMEN1ALDH1A1LMNA | |
| Omaciclovir SCHEMBL10507800 | 0.99 | TK1 (0.61) | TK1BLMMEN1ALDH1A1LMNA | |
| Omaciclovir SCHEMBL571367 | 0.95 | HPRT1 (0.66) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL10506595 | 0.95 | TK1 (0.65) | TK1BLMMEN1ALDH1A1LMNA | |
| Tiviciclovir SCHEMBL6944256 | 0.92 | BLM (0.67) | TK1BLMMEN1ALDH1A1LMNA | |
| Omaciclovir SCHEMBL9430446 | 0.92 | TK1 (0.55) | TK1BLMMEN1ALDH1A1LMNA | |
| Tiviciclovir SCHEMBL7745021 | 0.91 | BLM (0.66) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL10507335 | 0.91 | TK1 (0.67) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL16488939 | 0.91 | TK1 (0.60) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL10509880 | 0.90 | TK1 (0.69) | TK1BLMMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024167952-A1 | OXIDATIVELY CLEAVABLE ORGANOPHOSPHATE DRUGS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2024118480-A1 | USE OF ANTIVIRAL AGENTS, COMPOSITION OF MATTER, COMBINATION PREPARATIONS/AGENTS TO TREAT CHRONIC DISEASES ASSOCIATED WITH EPSTEIN-BARR VIRUS AND OTHER HUMAN HERPES VIRUSES | EPIPHANY BIOSCIENCES (US) | 2024-06-06 | — | — | WO | claimed |
| US-20230158000-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRAL HEPATITIS AND THE USE THEREOF | HOLY HAID LAB CORP (CN) | 2023-05-25 | — | — | US | claimed |
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| CN-121401266-A | Application of omalovir in inhibiting influenza A virus | 福建农林大学 | 2026-01-27 | — | — | CN | disclosed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| WO-2024174020-A1 | HERPES ZOSTER TREATMENT | XBIOTECH INC. (CA) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024163327-A1 | EPSTEIN-BARR VIRUS GLYCOPROTEIN 42 IMMUNOGENS FOR VACCINATION AND ANTIBODY DISCOVERY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024118480-A1 | USE OF ANTIVIRAL AGENTS, COMPOSITION OF MATTER, COMBINATION PREPARATIONS/AGENTS TO TREAT CHRONIC DISEASES ASSOCIATED WITH EPSTEIN-BARR VIRUS AND OTHER HUMAN HERPES VIRUSES | EPIPHANY BIOSCIENCES (US) | 2024-06-06 | — | — | WO | disclosed |
| US-5869493-A | ANTIVIRALS AGAINST HERPES AND RETROVIRUSES | MEDIVIR AB (SE) | 1999-02-09 | — | — | US | disclosed |
| EP-0888348-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880521-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | Medivir Aktiebolag (SE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998034917-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1998-08-13 | — | — | WO | disclosed |
| WO-1997030052-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030051-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1995007910-A1 | ANTIVIRAL INDOLE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995005179-A1 | THERAPEUTIC COMBINATION CONTAINING AN ANTI-VARICELLA ZOSTER VIRUS COMPOUND AND LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158000-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRAL HEPATITIS AND THE USE THEREOF | SLC10A1, HAVCR2, SLC10A2 | TK1 2014/4885BLM 780/4885MEN1 1304/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | TK1 2109/4885BLM 1124/4885MEN1 419/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | TK1 3492/4885BLM 1987/4885MEN1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.